Oligodendroglioma Research Fund
Through the Community Research Fund Program, the Oligodendroglioma Research Fund supports promising research specifically targeted at creating new treatments for oligodendroglioma and improving patients’ lives.
THE RESEARCH
From 2013 to today, NBTS has funded a total of $2 million in grants to 11 researchers across nine different institutions, all focused on oligodendroglioma and related low-grade glioma research. During this period, NBTS’s strategy to address the problem has focused on funding research projects that revealed genetic risk factors, established models capable of testing potential treatments, built scientific infrastructure to predict if treatments will work, launched novel therapeutic approaches, and helped propel a groundbreaking treatment toward a pivotal clinical trial lead by a biopharma prepared to bring a new therapy to patients. The latest Oligodendroglioma Research Progress Report focuses specifically on NBTS funded research related to oligodendroglioma. It describes results over a seven year time span and exciting next steps to drive research forward aimed at novel treatments and ultimately, cures.
Download the 2020 Oligo Research Progress Report.
Funded Projects Include:
- Innovative Models Developed for Testing Treatments
Dr. Anders Persson, University of California San Francisco - New Strategy Identified for Eliminating Brain Tumors
Drs. Mario Suva & David Louis, Massachusetts General Hospital - Targeting Mutant IDH 1/2 with Vorasidenib (AG-881) in Low-Grade Gliomas
Dr. Ingo Mellinghoff, Memorial Sloan Kettering Cancer - Leads Discovered About the Causes of Brain Cancer
Drs. Robert Jenkins & Daniel Lachance, Mayo Clinic - Registry Built to Learn from Every Patient and Determine Response to Treatment
Dr. Elizabeth Claus, Yale University - Identifying Risk Factors for Oligodendroglioma
Drs. Robert Jenkins & Daniel Lachance, Mayo Clinic - AI Platform Established to Predict Brain Tumor Behavior
Dan Brat and Lee Cooper, Emory and Northwestern University - International Consortium of Researchers Establishes Open Dataset Tracking Low-Grade Gliomas including Oligodendroglioma
Dr. Roel Verhaak, The Jackson Laboratory - Triggering the Body’s Immune System to Fight Back
Dr. Samuel Cheshier, Standford